Pharmacological chaperone therapy for fabry disease

Fabry Disease

Volumn , Issue , 2010, Pages 455-468

  Fan, Jian Qiang ^a   Ishii, Satoshi ^b  

^a Pfantastic Medical Research Institute   (United States)

^b OITA UNIVERSITY   (Japan)

Author keywords

1 deoxygalactonojirimycin; Active site specific chaperone; Endoplasmic reticulum associated degradation (ERAD); Pharmacological chaperone; Protein misfolding

Indexed keywords

EID: 84860510743     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-9033-1_29     Document Type: Chapter

References (40)

1. Brady RO (2006) Emerging strategies for the treatment of hereditary metabolic storage disorders. Rejuvenation Res 9(2):237-244
2. Fan JQ (2008) A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem 389(1):1-11
3. Platt FM, Jeyakumar M, Andersson U et al (2003) Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci 358(1433):947-954
4. Abe A, Gregory S, Lee L et al (2000) Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 105(11):1563-1571
5. Cox TM, Platt FM, Aerts JMFG (2007) Medicinal use of iminosugars. In: Compain P, Martin OR (eds) Iminosugars: from synthesis to therapeutic application. John Wiley & Sons Ltd, West Sussex, pp 295-326
6. Fan JQ, Ishii S (2007) Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. Febs J 274(19):4962-4971
7. Conn PM, Janovick JA (2009) Drug development and the cellular quality control system. Trends Pharmacol Sci 30(5):228-233
8. Bernier V, Lagace M, Bichet DG et al (2004) Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab 15(5):222-228
9. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding diseases. Nature 426(6968):905-909
10. Anfinsen CB, Scheraga HA (1975) Experimental and theoretical aspects of protein folding. Adv Protein Chem 29:205-300
11. Ellgaard L, Helenius A (2003) Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 4(3):181-191
12. Hartl FU, Hayer-Hartl M (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295(5561):1852-1858
13. Oda Y, Hosokawa N, Wada I et al (2003) EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin. Science 299(5611):1394-1397
14. Fewell SW, Travers KJ, Weissman JS et al (2001) The action of molecular chaperones in the early secretory pathway. Annu Rev Genet 35:149-191
15. Schubert U, Anton LC, Gibbs J et al (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404(6779):770-774
16. Yewdell JW (2001) Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 11(7):294-297
17. Kuznetsov G, Nigam SK (1998) Folding of secretory and membrane proteins. N Engl J Med 339:1688-1695
18. Ellgaard L, Molinari M, Helenius A (1999) Setting the standards: quality control in the secretory pathway. Science 286(5446):1882-1888
19. Pasyk EA, Foskett JK (1995) Mutant (DF508) cystic fibrosis transmembrane conductance regulator Cl-channel is functional when retained in endoplasmic reticulum of mammalian cells. J Biol Chem 270:12347-12350
20. Meacham GC, Patterson C, Zhang W et al (2001) The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol 3(1):100-105
21. Brady OR, Gal AE, Bradley RM et al (1967) Enzymatic defect in Fabry's disease: ceramide-trihexosidase deficiency. N Engl J Med 276:1163-1167
22. Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337(2):319-335
23. Garman SC, Garboczi DN (2002) Structural basis of Fabry disease. Mol Genet Metab 77(1-2):3-11
24. Ishii S, Kase R, Sakuraba H et al (1993) Characterization of a mutant α-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Comm 197:1585-1589
25. Ishii S, Suzuki Y, Fan J-Q (2000) Role of Ser-65 in the activity of alpha-galactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease. Arch Biochem Biophys 377(2):228-233
26. Ishii S, Chang HH, Kawasaki K et al (2007) Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 406(2):285-295
27. Yasuda K, Chang HH, Wu HL et al (2004) Efficient and rapid purification of recombi-nant human alpha-galactosidase A by affinity column chromatography. Protein Expr Purif 37(2):499-506
28. Helenius A, Aebi M (2004) Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem 73:1019-1049
29. Fan J-Q (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 24(7):355-360
30. Fan J-Q, Ishii S, Asano N et al (1999) Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 59(1):112-115
31. Asano N, Ishii S, Kizu H et al (2000) In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 267:4179-4186
32. Hamanaka R, Shinohara T, Yano S et al (2008) Rescue of mutant alpha-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes. Biochim Biophys Acta 1782(6):408-413
33. Shin SH, Murray GJ, Kluepfel-Stahl S et al (2007) Screening for pharmacological chaperones in Fabry disease. Biochem Biophys Res Commun 359(1):168-173
34. Shin SH, Kluepfel-Stahl S, Cooney AM et al (2008) Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet Genomics 18(9):773-780
35. Benjamin ER, Flanagan JJ, Schilling A et al (2009) The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis 32(3):424-440
36. Ishii S, Kase R, Sakuraba H et al (1998) α-Galactosidase transgenic mouse: heterogeneous gene expression and posttranslational glycosylation in tissues. Glycoconj J 15:591-594
37. Ohshima T, Murray GJ, Swaim WD et al (1997) α-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 94:2540-2544
38. Ishii S, Chang HH, Yoshioka H et al (2009) Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. J Pharmacol Exp Ther 328(3):723-731
39. Frustaci A, Chimenti C, Ricci R et al (2001) Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 345(1):25-32
40. Porto C, Cardone M, Fontana F et al (2009) The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibrob-lasts. Mol Ther 17(6):964-971